Zai Lab (ZLAB) Projected to Post Quarterly Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is expected to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $125.66 million for the quarter. Zai Lab has set its FY 2025 guidance at EPS.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.05. Zai Lab had a negative net margin of 60.26% and a negative return on equity of 33.35%. The company had revenue of $106.49 million for the quarter, compared to analyst estimates of $118.40 million. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Stock Performance

NASDAQ:ZLAB opened at $38.57 on Thursday. Zai Lab has a one year low of $16.01 and a one year high of $44.34. The firm has a market cap of $4.28 billion, a price-to-earnings ratio of -15.49 and a beta of 0.99. The firm’s fifty day moving average is $35.80 and its two-hundred day moving average is $32.64.

Insider Transactions at Zai Lab

In related news, CFO Yajing Chen sold 2,675 shares of the company’s stock in a transaction dated Thursday, June 26th. The shares were sold at an average price of $36.13, for a total transaction of $96,647.75. Following the completion of the transaction, the chief financial officer owned 21,004 shares in the company, valued at $758,874.52. This represents a 11.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William Lis sold 13,814 shares of the company’s stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $35.67, for a total transaction of $492,745.38. Following the transaction, the director owned 35,106 shares of the company’s stock, valued at approximately $1,252,231.02. This trade represents a 28.24% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 160,155 shares of company stock valued at $4,959,535 in the last ninety days. 4.96% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zai Lab stock. Royal Bank of Canada increased its stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ZLAB shares. Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the company an “outperform” rating in a report on Monday, June 30th. Wall Street Zen lowered shares of Zai Lab from a “buy” rating to a “hold” rating in a research note on Friday, June 27th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $54.28.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.